The Exclusive Domestic AI-PBPK Drug R&D Platform

B²O Pharmaceutical’s AI-PBPK platform breaks the boundaries of traditional drug development. Empowered by artificial intelligence for physiologically based pharmacokinetic modeling, it delivers precise prediction across the full lifecycle from early candidate screening to clinical endpoint evaluation. The platform features two exclusive strengths: it is the only dedicated PBPK platform developed in China, and globally unique in its deep integration of AI algorithms with PBPK modeling, delivering distinctive value for pharmaceutical R&D partners.